Abstract 458P
Background
Venous Thromboembolism (VTE) is a common cardiovascular disease affecting cancer patient with related poor prognosis and short survival. Different scoring systems and certain genetic polymorphisms were used to predict patient's risk for VTE. This study aimed to investigate the association between TSPAN15 (rs78707713) and SLC44A2 (rs2288904) genetic polymorphisms and VTE in cancer patients in correlation with PROTECHT scoring system and survival.
Methods
This case control study was carried out on 100 cancer patients, group I included 50 consecutive cancer patients with VTE, and group II included 50 selected cancer patients without VTE with age and cancer diagnosis matched to group I as a control. Full history taking and clinical examination and all clinical data were recorded. Laboratory investigations including CBC, coagulation profile and analysis of TSPAN15 (rs78707713) and SLC44A2 (rs2288904) SNPs by PCR were assessed. Radiological imaging of VTE by duplex ultrasound, CT pulmonary angiography were done according to the clinical scenario. PROTECHT score and survival analysis were calculated.
Results
Cancer patients with VTE had high tumor grade, increased incidence of metastasis with shorter progression free survival (PFS) compared with cancer patients without VTE. Partial immobilization and hospitalization were significantly associated with the occurrence of VTE in cancer patients. Regarding cancer treatment, the use of gemcitabine-based chemotherapy was associated with an increased risk for VTE. The most frequent SLC44A2 (rs2288904) genotype was GG followed by AG in cancer patients with VTE. Whereas GG and AG genotypes were equally distributed in cancer patients without VTE, The GG genotype had high risk PROTECHT score compared with AA and AG genotypes. The commonest TSPAN15 (rs78707713) genotypes were TC and CC in cancer patients with VTE versus TC and TT in cancer patients without VTE. The CC genotype had high PROTECHT score points compared with TC and TT genotypes. Furthermore, TC and CC cancer patients with VTE had significantly high tumor grade.
Conclusions
Screening of SLC44A2 (rs2288904) and TSPAN15 (rs78707713) genetic variants may enhance the ability to predict VTE risk in cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Menoufeya University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
280P - Radium-223 for patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases progressing after first-line abiraterone or enzalutamide: One institutional experience
Presenter: Keng Man Chiang
Session: Poster Display
Resources:
Abstract
281P - 10-year treatment outcome of prostate cancer patients with 3D conformal radiation: Experience of a single cancer institution in Iran
Presenter: Reyhane Bayani
Session: Poster Display
Resources:
Abstract
282P - Predictors of outcomes in patients with clinically lymph node-positive prostate cancer after definitive radiotherapy
Presenter: Jae-Sung Kim
Session: Poster Display
Resources:
Abstract
283P - Radiotherapy utilization rate and treatment patern of protate cancer at Cipto Mangunkusumo Central General Hospital (RSCM): What we learn from pre-pandemic era
Presenter: Riyan Apriantoni
Session: Poster Display
Resources:
Abstract
284TiP - CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer
Presenter: Nobuaki Matsubara
Session: Poster Display
Resources:
Abstract
292P - Comparative characteristics of early cervical cancer diagnosis methods for Tashkent women
Presenter: Gulnoza Goyibova
Session: Poster Display
Resources:
Abstract
293P - Carboplatin in locally advanced cervical cancer treated with chemoradiation: An alternative to cisplatin
Presenter: Natalia Isabel Valdiviezo Lama
Session: Poster Display
Resources:
Abstract
294P - Concurrent chemoradiation with cisplatin every 3 weeks in locally advanced cervical cancer: A single arm phase II clinical trial
Presenter: Long Nguyen
Session: Poster Display
Resources:
Abstract
295P - A prospective study of dose escalated simultaneous integrated boost in node-positive cervical cancer
Presenter: Ritusha Mishra
Session: Poster Display
Resources:
Abstract
296P - Safety, efficacy, and immunogenicity of therapeutic vaccines for patients with high-grade cervical intraepithelial neoplasia (CIN 2/3) associated with human papillomavirus: A systematic review
Presenter: Caroline Amélia Gonçalves
Session: Poster Display
Resources:
Abstract